---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References"
description: "Reference list for the formulary evidence report on Lonimecgene renparvovec (TSHA-102) in Rett syndrome. 199 cited documents."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References

<a id="references"></a>

## 5 References

1. [Abbott et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11502282/)
2. [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf)
3. [Acadia Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526072519/acad-20251231.htm)
4. [Amir et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10508514/)
5. [Anderson et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4078387/)
6. [Ben-Zeev et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13615242/)
7. [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)
8. [Berry-Kravis et al. (2026b)](https://tayshagtx.com/wp-content/uploads/CNS-2026-REVEAL-12mo-data-encore-poster_approval.pdf)
9. [Bienvenu et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16647997/)
10. [Bisgaard et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34296518/)
11. [Blue Shield of California (2023)](https://blueshieldca.com/content/dam/bsca/en/provider/docs/medical-policies/Genetic-Test-Rett-Syndrome.pdf)
12. [Boban et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29704311/)
13. [Bond et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41267498/)
14. [Buchanan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9107202/)
15. [Byiers et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3992319/)
16. [CDA-AMC trofinetide reimbursement recommendation (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829/2636?inline=1)
17. [CDA-AMC trofinetide reimbursement review (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829r/2969?inline=1)
18. [Cherchi et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10605630/)
19. [Cherchi et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38721909/)
20. [Choi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12428351/)
21. [ClinicalTrials.gov NCT00299312](https://clinicaltrials.gov/study/NCT00299312)
22. [ClinicalTrials.gov NCT02738281](https://clinicaltrials.gov/study/NCT02738281)
23. [ClinicalTrials.gov NCT04181723](https://clinicaltrials.gov/study/NCT04181723)
24. [ClinicalTrials.gov NCT04279314](https://clinicaltrials.gov/study/NCT04279314)
25. [ClinicalTrials.gov NCT04776746](https://clinicaltrials.gov/study/NCT04776746)
26. [ClinicalTrials.gov NCT04988867](https://clinicaltrials.gov/study/NCT04988867)
27. [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)
28. [ClinicalTrials.gov NCT05898620](https://clinicaltrials.gov/study/NCT05898620)
29. [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)
30. [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564)
31. [Corchón et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30220073/)
32. [Cosand et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875184/)
33. [Crosson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5444992/)
34. [Cuddapah et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4403764/)
35. [Cutri-French et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8882337/)
36. [Desnous et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10839357/)
37. [Devidze et al. (2023)](https://tayshagtx.com/wp-content/uploads/Design-of-the-REVEAL-Pediatric-study-of-TSHA-102-gene-therapy-for-Rett-Syndrome.pdf)
38. [Downs et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19644320/)
39. [Downs et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4603139/)
40. [Downs et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26661519/)
41. [Downs et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5764021/)
42. [Downs et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30460513/)
43. [Downs et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11663341/)
44. [EMA Daybu EPAR (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/daybu)
45. [EMA paediatric investigation plan decision (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232894-ema-decision-14-april-2025-agreement-paediatric-investigation-plan-granting-deferral-adeno-associated-viral-vector-serotype-9-containing-human-mecp2-gene_en.pdf-0)
46. [Epstein et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26686505/)
47. [Fang et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9034674/)
48. [FDA Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations draft guidance (2025)](https://www.fda.gov/media/188892/download)
49. [FDA Orphan Drug Designations and Approvals (2020)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=770520)
50. [FDA UNII NVK87P6NXW](https://precision.fda.gov/uniisearch/srs/unii/NVK87P6NXW)
51. [Fehr et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3906205/)
52. [Fehr et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3152673/)
53. [Fonzo et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7407501/)
54. [Freilinger et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20573179/)
55. [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)
56. [Fu et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7509967/)
57. [Galán-Olleros et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39429113/)
58. [Glaze et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2836870/)
59. [Gold et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39511247/)
60. [Greenwood Genetic Center](https://ggc.org/tests/rett-syndrome-mecp2-sequencing/)
61. [Guy et al. (2007)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7610836/)
62. [Hagberg et al. (1983)](https://pubmed.ncbi.nlm.nih.gov/6638958/)
63. [Haque et al. (2023)](https://tayshagtx.com/wp-content/uploads/The-microRNA-responsive-autoregulatory-element-from-TSHA-102-for-Rett-Syndrome-modulates-therapeutic-transgene-expression-in-response-to-cellular-MeCP2-in-mouse-and-human-cell-lines.pdf)
64. [Haque et al. (2024)](https://tayshagtx.com/wp-content/uploads/Broad-CNS-Biodistribution-of-AAV9-based-Gene-Therapies-Delivered-by-Intrathecal-Lumbar-Puncture-in-Non-Human-Primates.pdf)
65. [Haque et al. (2025)](https://tayshagtx.com/wp-content/uploads/rAAV9-Vector-Biodistribution-in-Brain-and-Spinal-Cord-via-Lumbar-Intrathecal-Infusion-in-Nonhuman-Primates-NHP-Assessing-the-Administration-Route-Leveraged-in-TSHA-102-Rett-Syndrome-Clinical-Trials.pdf)
66. [Haque et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13167494/)
67. [Haque et al. (2026b)](https://tayshagtx.com/wp-content/uploads/ASGCT-Superior-expression-of-self-complementary-AAV-and-comparable-functionality-of-mini-and-full-length-MECP2-support-the-design-of-TSHA-102-gene-therapy-for-Rett-syndrome.pdf)
68. [Hendrie et al. (2011)](https://doi.org/10.1016/j.rasd.2010.10.004)
69. [Hryniewiecka-Jaworska et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11975466/)
70. [ICH E11A guideline (2024)](https://database.ich.org/sites/default/files/ICH_E11A_Guideline_Step4_2024_0821.pdf)
71. [Jefferson et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4743907/)
72. [Kaufmann et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11323357/)
73. [Kaur and Christodoulou (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1497/)
74. [Keeley et al. (2025)](https://tayshagtx.com/wp-content/uploads/Every-Gain-Expanding-Possibilities-Caregiver-Insights-on-Meaningful-Improvement-in-Rett-Syndrome-Gene-Therapy-GT.pdf)
75. [Killian et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4899118/)
76. [Killian et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5461984/)
77. [Kim et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39255539/)
78. [Kirby et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2794941/)
79. [Krajnc (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4468994/)
80. [Kyle et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5830535/)
81. [Lane et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3233210/)
82. [Laurvick et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16615965/)
83. [Levy-Shraga et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12602358/)
84. [Lotan (2019)](https://pubmed.ncbi.nlm.nih.gov/30644545/)
85. [MacKay et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29536504/)
86. [Maheshwari (2018)](https://www.ai-online.info/images/ai-ausgabe/2018/04-2018/orphan-supplement-6-2018/2018_4_S117-S124_Rett%20syndrome.pdf)
87. [Managed Healthcare Executive (2023)](https://www.managedhealthcareexecutive.com/view/fda-approves-first-treatment-for-rett-syndrome)
88. [May et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10071755/)
89. [May et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10842289/)
90. [May et al. (2024b)](https://acadia.com/en-us/pdf/healthcare-professionals/scientific-publications/congress-materials/2024_EAN_May_HTA_SLR_Pos.pdf)
91. [May et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11282812/)
92. [McArthur and Budden (1998)](https://pubmed.ncbi.nlm.nih.gov/9566656/)
93. [McGraw et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37161302/)
94. [McKnight et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9135956/)
95. [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)
96. [Moore et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10960750/)
97. [Motil et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38869952/)
98. [Nemours (2026)](https://www.nemours.org/content/dam/nemours/nemours-org/en/documents/molecular-diagnostic-lab-cpt-codes-and-billing.pdf)
99. [Neul et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2677974/)
100. [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)
101. [Neul et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4112822/)
102. [Neul et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4610825/)
103. [Neul et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6488031/)
104. [Neul et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35149233/)
105. [Neul et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10287558/)
106. [Neul et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10939125/)
107. [Neul et al. (2023c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10571464/)
108. [Neul et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094048/)
109. [Neurogene third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000064/ngne_3qye26earningsrelease.htm)
110. [NINDS](https://www.ninds.nih.gov/health-information/disorders/rett-syndrome)
111. [Okposo et al. (2023)](https://tayshagtx.com/wp-content/uploads/A-Human-ready-Regulated-AAV9miniMECP2-miRARE-Gene-Therapy-TSHA-102-Improves-Survival-Weight-and-Behavior-After-Intracerebroventricular-ICV-Dosing-in-the-Neonatal-Knockout-Rett-RTT-Mouse-Model.pdf)
112. [Patel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/40820925/)
113. [Percy et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3021984/)
114. [Percy et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38917793/)
115. [Percy et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39025065/)
116. [Percy et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40043705/)
117. [Percy et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380397/)
118. [Peron et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8685662/)
119. [Peters et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12354067/)
120. [Petriti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9841621/)
121. [Pimprikar et al. (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2026/poster-session-2-4/the-impact-of-caring-for-their-children-with-rett-syndrome-a-multi-method-study)
122. [Prange et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13359341/)
123. [Prasad et al. (2022a)](https://tayshagtx.com/wp-content/uploads/ASGCT-2022-Safety-and-Biodistribution-Assessment-in-Non-Human-Primates-NHP-of-a-miniMECP2-AAV9-Vector-for-Gene-Replacement-Therapy-of-Rett-Syndrome.pdf)
124. [Prasad et al. (2022b)](https://tayshagtx.com/wp-content/uploads/Safety-Assessment-of-High-Dose-miniMECP2-AAV9-Gene-Replacement-Therapy-TSHA-102-for-Rett-Syndrome-in-Rats.pdf)
125. [Pulles et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13721293/)
126. [Quarmley et al. (2026)](https://tayshagtx.com/wp-content/uploads/Establishing-the-Rett-Syndrome-Developmental-Milestone-Assessment-RS-DMA-as-a-Primary-Endpoint-for-Interventional-Studies-2.pdf)
127. [Rajagopalan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12580911/)
128. [Rashid et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12082938/)
129. [Rashid et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12549289/)
130. [Rashid et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396111/)
131. [Rashid et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13264036/)
132. [Rashid et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556918/)
133. [Raspa et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7778880/)
134. [Rossignol et al. (2023)](https://tayshagtx.com/wp-content/uploads/Early-safety-and-efficacy-observations-following-the-first-use-of-TSHA-102-gene-therapy-in-a-patient-with-Rett-Syndrome.pdf)
135. [Rossignol et al. (2024a)](https://tayshagtx.com/wp-content/uploads/Early-safety-and-efficacy-observations-following-the-first-use-of-TSHA-102-gene-therapy-in-patients-with-Rett-Syndrome.pdf)
136. [Rossignol et al. (2024b)](https://tayshagtx.com/wp-content/uploads/TSHA-102-gene-therapy-for-Rett-syndrome-First-cohort-data-from-the-REVEAL-Adolescent-Adult-and-Pediatric-studies.pdf)
137. [Rossignol et al. (2025a)](https://tayshagtx.com/wp-content/uploads/REVEAL-AdolescentAdult-and-Pediatric-Clinical-Trial-Update-Safety-and-Efficacy-Data-on-TSHA-102-AAV9-Investigational-Gene-Therapy-in-Clinical-Evaluation-for-Rett-Syndrome.pdf)
138. [Rossignol et al. (2025b)](https://tayshagtx.com/wp-content/uploads/Achieving-Developmental-Milestones-and-Broad-Restoration-of-Function-in-Rett-Syndrome-The-Potential-of-TSHA-102-Gene-Therapy.pdf)
139. [Rozensztrauch et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8111277/)
140. [Sadhu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10815157/)
141. [Samanta (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12864443/)
142. [Sarajlija et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25571926/)
143. [Sigafoos et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37526342/)
144. [Singh et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7828978/)
145. [Sinnett et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8783608/)
146. [Skrobanski et al. (2025)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2025/poster-session-5-2/the-estimation-of-utility-weights-from-the-rett-syndrome-behavior-questionnaire)
147. [Stallworth et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6556084/)
148. [Stone et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37642479/)
149. [Strugnell et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31074665/)
150. [Symons et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3707000/)
151. [Ta et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8939085/)
152. [Tarquinio et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3468773/)
153. [Tarquinio et al. (2015a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4442062/)
154. [Tarquinio et al. (2015b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4609589/)
155. [Tarquinio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5278305/)
156. [Tarquinio et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6026556/)
157. [Tarquinio et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12970060/)
158. [Tascini et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8923297/)
159. [Taylor et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36882895/)
160. [Taysha Gene Therapies 54th CNS Annual Meeting supplemental analysis announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525235212/d949053dex991.htm)
161. [Taysha Gene Therapies adolescent eligibility announcement (2023)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-expanded-eligibility-reveal)
162. [Taysha Gene Therapies August 2026 corporate presentation (2026)](https://ir.tayshagtx.com/static-files/8da485f7-d48d-42b8-8fa7-388d58d55487)
163. [Taysha Gene Therapies Breakthrough Therapy designation announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525227505/d61846dex991.htm)
164. [Taysha Gene Therapies Catalent commercial manufacturing announcement (2026)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-and-catalent-expand-strategic-partnership)
165. [Taysha Gene Therapies clinical program update announcement (2024)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-updates-tsha-102-clinical)
166. [Taysha Gene Therapies European orphan designation announcement (2021)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-receives-orphan-drug-designation-european-commission-tsha)
167. [Taysha Gene Therapies Fast Track designation announcement (2023)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-fast-track-designation-granted)
168. [Taysha Gene Therapies first participant dosed announcement (2023)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-first-patient-dosed-tsha-102)
169. [Taysha Gene Therapies first pediatric participant dosed announcement (2024)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-first-pediatric-patient-dosed)
170. [Taysha Gene Therapies first quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526207633/d99032dex991.htm)
171. [Taysha Gene Therapies first-cohort data HCP presentation (2024)](https://tayshagtx.com/wp-content/uploads/First-cohort-Data-from-the-REVEAL-AdolescentAdult-and-Pediatric-Studies-of-TSHA-102-Gene-Therapy-for-Rett-Syndrome-1.pdf)
172. [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)
173. [Taysha Gene Therapies full rights announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525241415/d35488dex991.htm)
174. [Taysha Gene Therapies full-year 2024 results announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525035882/d920809dex991.htm)
175. [Taysha Gene Therapies full-year 2025 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115177/d46409dex991.htm)
176. [Taysha Gene Therapies healthcare professionals page](https://tayshagtx.com/healthcare-professionals/)
177. [Taysha Gene Therapies June 2026 program update presentation (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex992.htm)
178. [Taysha Gene Therapies low dose cohort data announcement (2024)](https://www.sec.gov/Archives/edgar/data/1806310/000119312524163050/d851091dex991.htm)
179. [Taysha Gene Therapies orphan drug and rare pediatric disease designation announcement (2020)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-receives-rare-pediatric-disease)
180. [Taysha Gene Therapies our science page](https://tayshagtx.com/our-science/)
181. [Taysha Gene Therapies pivotal program progress announcement (2026)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-progress-across-tsha-102-pivotal)
182. [Taysha Gene Therapies pivotal trial design announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525129494/d904503dex991.htm)
183. [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm)
184. [Taysha Gene Therapies RMAT designation announcement (2024)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-regenerative-medicine-advanced)
185. [Taysha Gene Therapies second quarter 2025 results announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525178504/d51118dex991.htm)
186. [Taysha Gene Therapies second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm)
187. [Taysha Gene Therapies third quarter 2024 results announcement (2024)](https://www.sec.gov/Archives/edgar/data/1806310/000119312524257205/d877348dex991.htm)
188. [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)
189. [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)
190. [Townend et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4785214/)
191. [Townend et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32720526/)
192. [Trappe et al. (2001)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1226090/)
193. [Vidal et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5613000/)
194. [Vignoli et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12362169/)
195. [Vilvarajan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10454341/)
196. [WHO Proposed INN List 130 (2023)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl130.pdf)
197. [Wiedemann et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30554334/)
198. [Wong et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29941161/)
199. [Young et al. (2007)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2527512/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
